摘要
目的探寻米尔贝类化合物尼莫克汀、米尔贝β1逆转人乳腺癌多药耐药细胞株(MCF-7/adr)多药耐药(multidrug resistance,MDR)的作用及机制。方法采用MTT比色法测定细胞生长抑制率及耐药指数;高效液相色谱(HPLC)检测细胞内阿霉素(ADR)的积累变化;荧光分光光度仪检测罗丹明123(Rh123)在肿瘤细胞内的积累;通过RT-PCR与流式细胞仪检测MDR1基因与P-糖蛋白(P-gp)表达的变化。结果 5μmol·L-1的尼莫克汀、米尔贝β1可明显增强MCF-7/adr对ADR的敏感性,增加细胞内ADR及Rh123的积累,且呈剂量依赖关系,不同程度降低MDR1和P-gp的表达。结论尼莫克汀、米尔贝β1对MCF-7/adr的耐药有一定的逆转作用,且尼莫克汀效果好于米尔贝β1。
Aim To explore the reversal of MDR( mul- tidrug resistance ) by nemadectin and milbemycin β1 from the milbemycin family to adriamycin-resistant hu- man breast carcinoma cells (MCF-7/adr). Methods MTI' assay was used to evaluate the cell suppression rates and reversal effects. Intracellular accumulation of adriamycin was determined by HPLC. The accumula- tion of rhodamine 123 ( Rh123 ) was measured with spectrofluorometer. The expressions of P-gp and the MDR1 gene encoding P-gp were tested by flow cytometry and reverse-transcriptase PCR. Results Nemadec- tin and milbemycin β1 at the high dose of 5μmol·L^-1 significantly increased the sensitivity of MCF-7/adrcells to adriamycin. They also increased the intracellu- lar accumulation of adriamycin and Rhl23 in MCF-7/ adr cells in a dose-dependent manner. Expression of both P-gp and MDR1 was down-regulated to different level. Conclusion Nemadectin and milbemycin β1 can partly reverse multidrug resistance of MCF-7/adr, and the effect of nemadectin is better than that of mil- bemycin β1.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2013年第10期1409-1413,共5页
Chinese Pharmacological Bulletin
基金
国家自然科学基金青年基金资助项目(No 81201723)
国家基础科学人才培养基金子项目(No J1210069-23)
东北农业大学博士启动基金(No 2012RCB35)
关键词
尼莫克汀
米尔贝β1
多药耐药
P-糖蛋白
人乳腺癌
阿霉素
nemadectin
milbemyein β1
muhidrug resistance
P-glycoprotein
human breast carcinoma
adriamycin